ADC Therapeutics SA (ADCT) Tops Q3 EPS by 10c

ADC Therapeutics SA (NYSE: ADCT) reported Q3 EPS of ($0.28), $0.10 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $18.46 million versus the consensus estimate of $18.46 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ross Stores, Inc. (ROST) PT Raised to $239 at UBS on Q2 Earnings Beat
• H.C. Wainwright Reiterates Buy Rating on Lifeward (LFWD)